Cerdá Begoña, Llorach Rafael, Cerón José J, Espín Juan Carlos, Tomás-Barberán Francisco A
Department of Food Science and Technology, CEBAS (CSIC), P. O. Box 4195, Murcia 30080, Spain.
Eur J Nutr. 2003 Jan;42(1):18-28. doi: 10.1007/s00394-003-0396-4.
BACKGROUND & AIMS: Punicalagin is an antioxidant ellagitannin of pomegranate juice. This compound is responsible for the high antioxidant activity of this juice. Nothing is known about the bioavailability and metabolism of punicalagin or other food ellagitannins. The present work aims to evaluate the bioavailability and metabolism of punicalagin in the rat as an animal model.
Two groups of rats were studied. One fed with standard rat diet (n = 5) and another with the same diet plus 6 % punicalagin (n = 5). Samples of urine and faeces were taken during 37 days and plasma every week. The different metabolites were analysed by HPLC-MS-MS.
The daily intake of punicalagin ranged from 0.6 to 1.2 g. Values around 3-6 % the ingested punicalagin were excreted as identified metabolites in faeces and urine. In faeces, punicalagin is transformed to hydrolysis products and partly metabolites by the rat microflora to 6H-dibenzo[b,d]pyran-6-one derivatives. In plasma, punicalagin was detected at concentrations around 30 microg/mL, and glucuronides of methyl ether derivatives of ellagic acid were also detected. 6H-Dibenzo[b,d]pyran-6-one derivatives were also detected especially during the last few weeks of the experiment. In urine, the main metabolites observed were the 6H-dibenzo[b,d]pyran-6-one derivatives, as aglycones or glucuronides.
As only 3-6 % of the ingested punicalagin was detected as such or as metabolites in urine and faeces, the majority of this ellagitannin has to be converted to undetectable metabolites (i. e. CO(2)) or accumulated in non-analysed tissues, however with only traces of punicalagin metabolites being detected in liver or kidney. This is the first report on the absorption of an ellagitannin and its presence in plasma. In addition, the transformation of ellagic acid derivatives to 6H-dibenzo[b,d]pyran-6-one derivatives in the rat is also confirmed.
石榴皮素是石榴汁中的一种抗氧化鞣花单宁。该化合物是石榴汁具有高抗氧化活性的原因。目前对于石榴皮素或其他食物中的鞣花单宁的生物利用度和代谢情况尚不清楚。本研究旨在以大鼠为动物模型评估石榴皮素的生物利用度和代谢情况。
对两组大鼠进行研究。一组喂食标准大鼠饲料(n = 5),另一组喂食相同饲料并添加6%的石榴皮素(n = 5)。在37天内采集尿液和粪便样本,每周采集血浆样本。通过高效液相色谱-串联质谱法分析不同的代谢产物。
石榴皮素的每日摄入量在0.6至1.2克之间。约3% - 6%摄入的石榴皮素以已鉴定的代谢产物形式在粪便和尿液中排泄。在粪便中,石榴皮素被大鼠微生物群转化为水解产物,并部分代谢为6H - 二苯并[b,d]吡喃 - 6 - 酮衍生物。在血浆中,检测到石榴皮素的浓度约为30微克/毫升,同时还检测到鞣花酸甲醚衍生物的葡萄糖醛酸苷。特别是在实验的最后几周也检测到了6H - 二苯并[b,d]吡喃 - 6 - 酮衍生物。在尿液中,观察到的主要代谢产物是6H - 二苯并[b,d]吡喃 - 6 - 酮衍生物,以苷元或葡萄糖醛酸苷的形式存在。
由于在尿液和粪便中仅检测到3% - 6%摄入的石榴皮素及其代谢产物,大部分这种鞣花单宁必定已转化为无法检测到的代谢产物(即二氧化碳)或积聚在未分析的组织中,然而在肝脏或肾脏中仅检测到微量的石榴皮素代谢产物。这是关于鞣花单宁吸收及其在血浆中存在情况的首次报告。此外,还证实了在大鼠体内鞣花酸衍生物向6H - 二苯并[b,d]吡喃 - 6 - 酮衍生物的转化。